Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
Refine search result
12 1 - 50 of 66
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Rows per page
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sort
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
Select
The maximal number of hits you can export is 250. When you want to export more records please use the Create feeds function.
  • 1. Banefelt, J.
    et al.
    Hallberg, S.
    Fox, K. M.
    Mesterton, J.
    Paoli, C. J.
    Johansson, Gunnar
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Levin, L. A.
    Sobocki, P.
    Gandra, S. R.
    Work Productivity Loss And Indirect Costs Associated With New Cardiovascular Events In High-Risk Patients With Hyperlipidemia - Estimates From Population-Based Register Data In Sweden2014In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 17, no 7, p. A327-A328, article id CV2Article in journal (Other academic)
  • 2. Banefelt, J.
    et al.
    Hallberg, S.
    Gandra, S. R.
    Mesterton, J.
    Fox, K. M.
    Paoli, C. J.
    Johansson, Gunnar
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Levin, L. A.
    Sobocki, P.
    Burden Of Hyperlipidemia Resulting From Productivity Loss - Estimates From Population-Based Register Data In Sweden2014In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 17, no 7, p. A491-A492, article id PCV110Article in journal (Other academic)
  • 3.
    Berg, Jenny
    et al.
    Swedish Agcy Hlth Technol Assessment & Assessment, Box 6183, SE-10233 Stockholm, Sweden..
    Kallen, Karin
    Lund Univ, Inst Clin Sci, Dept Obstet & Gynaecol, Unit Reprod Epidemiol,Tornblad Inst, Lund, Sweden..
    Andolf, Ellika
    Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Div Obstet & Gynaecol, Stockholm, Sweden..
    Hellström-Westas, Lena
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health.
    Ekéus, Cecilia
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health.
    Alvan, Jonatan
    Swedish Agcy Hlth Technol Assessment & Assessment, Box 6183, SE-10233 Stockholm, Sweden..
    Vitols, Sigurd
    Swedish Agcy Hlth Technol Assessment & Assessment, Box 6183, SE-10233 Stockholm, Sweden.;Karolinska Inst, Dept Med, Stockholm, Sweden..
    Economic Evaluation of Elective Cesarean Section on Maternal Request Compared With Planned Vaginal Birth-Application to Swedish Setting Using National Registry Data2023In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 26, no 5, p. 639-648Article in journal (Refereed)
    Abstract [en]

    Objectives: There is a lack of consensus around the definition of delivery by cesarean section (CS) on maternal request, and clinical practice varies across and within countries. Previous economic evaluations have focused on specific populations and selected complications. Our aim was to evaluate the cost-effectiveness of CS on maternal request compared with planned vaginal birth in a Swedish context, based on a systematic review of benefits and drawbacks and national registry data on costs.

    Methods: We used the results from a systematic literature review of somatic risks for long-and short-term complications for mother and child, in which certainty was rated low, moderate, or high using the Grading of Recommendations Assessment, Development and Evaluation. Swedish national registry data were used for healthcare costs of delivery and complications. Utilities for long-term complications were based on a focused literature review. We constructed a decision tree and conducted separate analyses for primi-and multiparous women. Costs and effects were discounted by 3% and the time horizon was varied between 1 and 20 years.

    Results: Planned vaginal birth leads to lower healthcare costs and somatic health gains compared with elective CS without medical indication over up to 20 years. Although there is uncertainty around, for example, quality-of-life effects, results remain stable across sensitivity analyses.

    Conclusions: CS on maternal request leads to increased hospitalization costs in a Swedish setting, taking into account short -and long-term consequences for both mother and child. Future research needs to study the psychological consequences related to different delivery methods, costs in outpatient care, and productivity losses.

    Download full text (pdf)
    fulltext
  • 4.
    Bjorstad, A.
    et al.
    Nord Hlth Econ, Gothenburg, Sweden..
    Marlow, T.
    Nord Hlth Econ, Gothenburg, Sweden..
    Lesen, E.
    Nord Hlth Econ, Gothenburg, Sweden..
    Bollano, E.
    Sahlgrens Univ Hosp, Gothenburg, Sweden..
    Marteau, F.
    Ipsen Pharma, Boulogne, France..
    Gabriel, S.
    Ipsen Pharma, Boulogne, France..
    Welin, Staffan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Endocrin Oncology.
    Fcuilly, M.
    Ipsen Pharma, Boulogne, France..
    Real-World Resource Use And Costs Of Carcinoid Heart Disease In Patients With Neuroendocrine Tumors: A Retrospective Swedish Study2017In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, no 9, p. A552-A552Article in journal (Other academic)
  • 5. Bostrom, P.
    et al.
    Lovkvist, L.
    Gustafsson, M.
    Alexandersson, O.
    Bruse, C.
    Liffner, C.
    Holmberg, J.
    Edlund, M.
    Olovsson, Matts
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Obstetrics and Gynaecology.
    Cost of illness in women with endometriosis2012In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 15, no 7, p. A538-A538Article in journal (Other academic)
  • 6. Brobert, G.
    et al.
    Garcia Rodriguez, L. A.
    Garbe, E.
    Bezemer, I. D.
    Layton, D.
    Friberg, L.
    Suzart-Woischnik, K.
    Alderson, J.
    Winchester, C.
    Herings, R. M. C.
    Jobski, K.
    Schink, T.
    Shakir, S.
    Soriano-Gabarro, M.
    Wallander, Mari-Ann
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Development of a Collaborative European Pharmacoepidemiologic Post-Authorization Safety Study (PASS) Programme Examining Rivaroxaban Use in Routine Clinical Practice2014In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 17, no 7, p. A473-A474, article id PCV6Article in journal (Other academic)
  • 7. Chen, Gang
    et al.
    Flynn, Terry
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Centre for Research Ethics and Bioethics.
    Stevens, Katherine
    Brazier, John
    Huynh, Elisabeth
    Sawyer, Michael
    Roberts, Rachel
    Ratcliffe, Julie
    Assessing the Health-Related Quality of Life of Australian Adolescents: An Empirical Comparison of the Child Health Utility 9D and EQ-5D-Y Instruments2015In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 18, no 4, p. 432-438Article in journal (Refereed)
    Abstract [en]

    Objectives: To examine the performance of two recently developed preference-based instruments-the Child Health Utility 9D (CHU9D) and the EuroQol five-dimensional questionnaire Youth version (EQ-5D-Y)-in assessing the health related quality of life (HRQOL) of Australian adolescents. Methods: An online survey including the CHU9D and the EQ-5D-Y, self-reported health status, and a series of sociodemographic questions was developed for administration to a community-based sample of adolescents (aged 11-17 years). Individual responses to both instruments were translated into utilities using scoring algorithms derived from the Australian adult general population. Results: A total of 2020 adolescents completed the online survey. The mean +/- SD utilities of the CHU9D and the EQ-5D-Y were very similar (0.82 +/- 0.13 and 0.83 +/- 0.19, respectively), and the intraclass correlation coefficient (0.80) suggested good levels of agreement. Both instruments were able to discriminate according to varying levels of self-reported health status (P < 0.001). Although exhibiting good levels of agreement overall, some wide divergences were apparent at an individual level. Conclusions: The study results are encouraging and illustrate the potential for both the CHU9D and the EQ-5D-Y to be more widely used for measuring and valuing the HRQOL of adolescent populations in Australia and internationally. Generating adolescent-specific scoring algorithms pertaining to each instrument and an empirical comparison of the resulting utilities is a natural next step. More evidence is required from the application of the CHU9D and the EQ-5D-Y in specific patient groups in adolescent health settings to inform the choice of instrument for measuring and valuing the HRQOL for the economic evaluation of adolescent health care treatments and services.

  • 8.
    Colson, Abigail R.
    et al.
    Univ Strathclyde, Strathclyde Business Sch, Management Sci, Glasgow, Lanark, Scotland..
    Morton, Alec
    Univ Strathclyde, Strathclyde Business Sch, Management Sci, Glasgow, Lanark, Scotland..
    Årdal, Christine
    Norwegian Inst Publ Hlth, Antimicrobial Resistance Ctr, Oslo, Norway..
    Chalkidou, Kalipso
    Imperial Coll London, Sch Publ Hlth, London, England..
    Davies, Sally C.
    UK Dept Hlth & Social Care, London, England..
    Garrison, Louis P.
    Univ Washington, Comparat Hlth Outcomes Policy & Econ Inst, Seattle, WA 98195 USA..
    Jit, Mark
    London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England..
    Laxminarayan, Ramanan
    Ctr Dis Dynam Econ & Policy, Washington, DC USA..
    Megiddo, Itamar
    Univ Strathclyde, Strathclyde Business Sch, Management Sci, Glasgow, Lanark, Scotland..
    Morel, Chantal
    Uppsala University, Disciplinary Domain of Humanities and Social Sciences, Faculty of Social Sciences, Department of Business Studies. Univ Hosp Bonn, Inst Hyg & Publ Hlth, Bonn, Germany; Univ Geneva, Sci Fac, Geneva Transformat Governance Lab, Geneva, Switzerland.
    Nonvignon, Justice
    Univ Ghana, Sch Publ Hlth, Dept Hlth Policy Planning & Management, Legon, Ghana..
    Outterson, Kevin
    Boston Univ, Sch Law, Boston, MA 02215 USA..
    Rex, John H.
    F2G Ltd, Eccles, Cheshire, England.;AMR Solut, Boston, MA USA..
    Sarker, Abdur Razzaque
    Bangladesh Inst Dev Studies, Dhaka, Bangladesh..
    Sculpher, Mark
    Univ York, Ctr Hlth Econ, York, N Yorkshire, England..
    Woods, Beth
    Univ York, Ctr Hlth Econ, York, N Yorkshire, England..
    Xiao, Yue
    Natl Ctr Med & Hlth Technol Assessment, China Natl Hlth Dev Res Ctr, Beijing, Peoples R China..
    Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?2021In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 24, no 12, p. 1828-1834Article in journal (Refereed)
    Abstract [en]

    Antimicrobial resistance is a serious challenge to the success and sustainability of our healthcare systems. There has been increasing policy attention given to antimicrobial resistance in the last few years, and increased amounts of funding have been channeled into funding for research and development of antimicrobial agents. Nevertheless, manufacturers doubt whether there will be a market for new antimicrobial technologies sufficient to enable them to recoup their investment. Health technology assessment (HTA) has a critical role in creating confidence that if valuable technologies can be developed they will be reimbursed at a level that captures their true value. We identify 3 deficiencies of current HTA processes for appraising antimicrobial agents: a methods-centric approach rather than problem-centric approach for dealing with new challenges, a lack of tools for thinking about changing patterns of infection, and the absence of an approach to epidemiological risks. We argue that, to play their role more effectively, HTA agencies need to broaden their methodological tool kit, design and communicate their analysis to a wider set of users, and incorporate long-term policy goals, such as containing resistance, as part of their evaluation criteria alongside immediate health gains.

    Download full text (pdf)
    FULLTEXT01
  • 9. Costa-Scharplatz, M.
    et al.
    Tambour, M.
    Henriksson, F.
    Ställberg, Björn
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Cost-Effectiveness Of Glycopyrronium Compared To Tiotropium In Copd Patients From A Swedish Societal Perspective2013In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 16, no 7, p. A371-A372Article in journal (Other academic)
  • 10.
    Feldman, Inna
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Social medicine/CHAP.
    Virtanen, S.
    Karolinska Inst, Stockholm, Sweden.
    Galanti, M. R.
    Karolinska Inst, Stockholm, Sweden.
    Johansson, P.
    Publ Hlth & Econ, Huddinge, Sweden.
    Economic Evaluation Of A Brief Counselling For Smoking Cessation In Dentistry: A Case Study Comparing Two Health Economic Models2017In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, no 9, p. A751-A751Article in journal (Other academic)
  • 11.
    Forbes, C. A.
    et al.
    Kleijnen Systemat Reviews Ltd, York, N Yorkshire, England..
    Deshpande, S.
    Kleijnen Systemat Reviews Ltd, York, N Yorkshire, England..
    Sorio-Vilela, F.
    Amgen Europe, Zug, Switzerland.;EEMEA, Zug, Switzerland..
    Kutikova, L.
    Amgen Europe GmbH, Zug, Switzerland..
    Duffy, S.
    Kleijnen Systemat Reviews Ltd, York, N Yorkshire, England..
    Gouni-Berthold, I
    Univ Cologne, Cologne, Germany..
    Hagström, Emil
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Cardiology.
    Comparison Of Methods To Measure Patient Adherence And Persistence With Pharmacological Therapy: A Systematic Review2017In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, no 9, p. A620-A620Article in journal (Other academic)
  • 12. Fränneby, Ulf
    et al.
    Sandblom, Gabriel
    Nyrén, Olof
    Nordin, Pär
    Gunnarsson, Ulf
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences.
    Self-reported adverse events after groin hernia repair, a study based on a national register2008In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 11, no 5, p. 927-932Article in journal (Refereed)
    Abstract [en]

    Objectives: In most clinics, follow-up after inguinal hernia surgery is not a routine procedure and complications may pass unnoticed, thus impairing quality assessment. The aim of this study was to investigate the frequency, spectrum, and risk factors of short-term adverse events after groin hernia repair. Methods: All patients aged 15 years or older with a primary unilateral inguinal or femoral hernia repair recorded in the Swedish Hernia Register (SHR) between November 1 and December 31, 2002 were sent a questionnaire asking about complications within the first 30 postoperative days. Results: Of the 1643 recorded patients, 1448 (88.1%) responded: 1341 (92.6%) were men and 107 (7.4%) women, mean age 59 years. There were 195 (11.9%) nonresponders. Postoperative complications reported in the questionnaire were hematoma in 203 (14.0%) patients, severe pain in 168 (11.6%), testicular pain in 120 (8.3%), and infection in 105 (7.3%). Adverse events were reported in the questionnaire by 391 (23.8%) patients, whereas only 85 (5.2%) were affected according to the SHR. Risk factors for postoperative complications were age below the median (59 years) among the studied hernia patients (OR 1.36; 95% CI 1.06-1.74) and laparoscopic repair (OR 2.66; 95% CI 1.17-6.05). Conclusion: Questionnaires provide valuable additional information concerning postoperative complications. We recommend that they become an integrated part of routine postoperative assessment.

  • 13.
    Fust, K.
    et al.
    Optum, Boston, MA USA..
    Maschio, M.
    Optum, Burlington, ON, Canada..
    Pastor, M.
    Optum, Burlington, ON, Canada..
    Kohli, M.
    Optum, Burlington, ON, Canada..
    Weinstein, M. C.
    Harvard TH Chan Sch Publ Hlth, Boston, MA USA..
    Singh, S.
    Sunnybrook Res Inst, Toronto, ON, Canada..
    Pritchard, M.
    Univ Liverpool, Liverpool, Merseyside, England..
    Welin, Staffan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Endocrin Oncology.
    Marteau, R.
    Ipsen Pharma, Boulogne, France..
    Gabriel, S.
    Ipsen Pharma, Boulogne, France..
    Feuilly, M.
    Ipsen Pharma, Boulogne, France..
    A Budget Impact Model Of The Addition Of Telotristat Ethyl Treatment In Patients With Uncontrolled Carcinoid Syndrome2017In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, no 9, p. A548-A549Article in journal (Other academic)
  • 14. Granstrom, O.
    et al.
    Kjeldsen, S. E.
    Russell, D.
    Thuresson, M.
    Stålhammar, Jan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Bodegard, J.
    Hedegaard, M.
    Hospitalizations and primary care resource use: A real-life perspective2012In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 15, no 4, p. A130-A130Article in journal (Other academic)
  • 15. Hallberg, S.
    et al.
    Banefelt, J.
    Fox, K. M.
    Mesterton, J.
    Johansson, Gunnar
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Levin, L. A.
    Sobocki, P.
    Gandra, S. R.
    Treatment Patterns In Hyperlipidemia Patients With New Cardiovascular Events - Estimates From Population-Based Register Data In Sweden2014In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 17, no 7, p. A501-A501, article id PCV162Article in journal (Other academic)
  • 16. Hallberg, S.
    et al.
    Banefelt, J.
    Mesterton, J.
    Gandra, S. R.
    Fox, K. M.
    Johansson, Gunnar
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Levin, L. A.
    Sobocki, P.
    Health Care Costs Associated With Cardiovascular Events In Patients With Hyperlipidemia - Estimates From Population-Based Register Data In Sweden2014In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 17, no 7, p. A492-A492, article id PCV111Article in journal (Other academic)
  • 17.
    Hansson-Hedblom, A.
    et al.
    Quantify Res, Stockholm, Sweden..
    Jonsson, E.
    Quantify Res, Stockholm, Sweden..
    Kirketeig, Terje
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Anaesthesiology and Intensive Care.
    Hägg, O.
    Spine Ctr Goteborg, Gothenburg, Sweden..
    Fritzell, P.
    Capio St Goran Hosp, Stockholm, Sweden..
    Borgström, F.
    Capio St Goran Hosp, Stockholm, Sweden..
    Cost Patterns In Patients Treated With Spinal Cord Stimulation Following Spine Surgery-A Register Based Study2016In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 19, no 7, p. A692-A692Article in journal (Refereed)
  • 18. Hedegaard, M.
    et al.
    Janson, Christer
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Respiratory Medicine and Allergology.
    Lisspers, Karin
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Ställberg, Björn
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Johansson, Gunnar
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Jorgensen, L.
    Larsson, K.
    Cost Effectiveness Of Budesonide/Formoterol Versus Fluticasone/Salmeterol From A Swedish Health Care Perspective Based On Real-World Effectiveness And Safety In Patients With Copd2013In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 16, no 3, p. A235-A235Article in journal (Other academic)
  • 19. Hedegaard, M.
    et al.
    Janson, Christer
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Respiratory Medicine and Allergology.
    Lisspers, Karin
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Ställberg, Björn
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Johansson, Gunnar
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Jorgensen, L.
    Larsson, K.
    Cost-effectiveness of budesonide/formoterol versus fluticasone/salmeterol based on real-world effectiveness in patients with copd2012In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 15, no 7, p. A563-A563Article in journal (Other academic)
  • 20. Huls, Samare P. I.
    et al.
    Veldwijk, Jorien
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Centre for Research Ethics and Bioethics. Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Erasmus Choice Modelling Centre, Erasmus University Rotterdam, Rotterdam, The Netherlands.
    Swait, Joffre D.
    Viberg Johansson, Jennifer
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Centre for Research Ethics and Bioethics. Department of New Technologies and the Human Future, The Institute for Future Studies, Stockholm, Sweden.
    Ancillotti, Mirko
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Centre for Research Ethics and Bioethics.
    de Bekker-Grob, Esther W.
    Preference Variation: Where Does Health Risk Attitude Come Into the Equation?2022In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 25, no 12, p. 2044-2052Article in journal (Refereed)
    Abstract [en]

    Objectives

    Decisions about health often involve risk, and different decision makers interpret and value risk information differently. Furthermore, an individual’s attitude toward health-specific risks can contribute to variation in health preferences and behavior. This study aimed to determine whether and how health-risk attitude and heterogeneity of health preferences are related.

    Methods

    To study the association between health-risk attitude and preference heterogeneity, we selected 3 discrete choice experiment case studies in the health domain that included risk attributes and accounted for preference heterogeneity. Health-risk attitude was measured using the 13-item Health-Risk Attitude Scale (HRAS-13). We analyzed 2 types of heterogeneity via panel latent class analyses, namely, how health-risk attitude relates to (1) stochastic class allocation and (2) systematic preference heterogeneity.

    Results

    Our study did not find evidence that health-risk attitude as measured by the HRAS-13 distinguishes people between classes. Nevertheless, we did find evidence that the HRAS-13 can distinguish people’s preferences for risk attributes within classes. This phenomenon was more pronounced in the patient samples than in the general population sample. Moreover, we found that numeracy and health literacy did distinguish people between classes.

    Conclusions

    Modeling health-risk attitude as an individual characteristic underlying preference heterogeneity has the potential to improve model fit and model interpretations. Nevertheless, the results of this study highlight the need for further research into the association between health-risk attitude and preference heterogeneity beyond class membership, a different measure of health-risk attitude, and the communication of risks.

    Download full text (pdf)
    fulltext
  • 21.
    Janssens, R.
    et al.
    Univ Leuven, Leuven, Belgium..
    Huys, I
    Katholieke Univ Leuven, Leuven, Belgium..
    van Overbeeke, E.
    Univ Leuven, Leuven, Belgium..
    Whichello, C.
    Erasmus Univ, Rotterdam, Netherlands..
    de Bekker-Grob, E.
    Erasmus Univ, Rotterdam, Netherlands..
    Kuebler, J.
    QSciCon, Marburg, Germany..
    Harding, S.
    Takeda Dev Ctr Europe Ltd, London, England..
    Juhaeri, J.
    Sanofi, Bridgewater, NJ USA..
    Levitan, B.
    Janssen R&D, Titusville, NJ USA..
    Cleemput, I
    Belgian Hlth Care Knowledge Inst KCE, Brussels, Belgium..
    Russo, S.
    European Inst Oncol, Milan, Italy..
    Schölin Bywall, Karin
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Centre for Research Ethics and Bioethics.
    Veldwijk, Jorien
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Centre for Research Ethics and Bioethics.
    Stakeholder Perspectives On The Integration Of Patient Preferences In The Medical Product Life Cycle: A Multimethod Approach2017In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, no 9, p. A689-A689Article in journal (Other academic)
  • 22. Johansson, S
    et al.
    Farahmand, B
    Joelson, S
    Estborn, L
    Wallander, Mari-Ann
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Risk of upper gastrointestinal adverse events and the effect of acid-suppressive theraphy in patients receiving acetylsalicylic acid for cardiovascular risk management2009In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 12, no 3, p. A58-Article in journal (Refereed)
  • 23.
    Jonsson, E.
    et al.
    Quantify Res, Stockholm, Sweden..
    Hanson-Hedblom, A.
    Quantify Res, Stockholm, Sweden..
    Kirketeig, Terje
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Anaesthesiology and Intensive Care.
    Fritzell, P.
    Capio St Goran Hosp, Stockholm, Sweden..
    Hagg, O.
    Spine Ctr Goteborg, Gothenburg, Sweden..
    Borgstrom, F.
    Quantify Res, Stockholm, Sweden..
    Societal Cost Patterns By Spine Surgical Outcome Groups And Patients Treated With Spinal Cord Stimulation Following Spine Surgery2017In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, no 9, p. A553-A553Article in journal (Other academic)
  • 24.
    Jonsson, E.
    et al.
    Quantify Res, Stockholm, Sweden..
    Strom, O.
    Quantify Res, Stockholm, Sweden.;Karolinska Inst, LIME MMC, Stockholm, Sweden..
    Spangeus, A.
    Linkoping Univ Hosp, Linkoping, Sweden..
    Akesson, K.
    Lund Univ, Skane Univ Hosp, Malmo, Sweden..
    Ljunggren, Östen
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Endocrinology and mineral metabolism.
    Borgstrom, R.
    Quantify Res, Stockholm, Sweden.;Karolinska Inst, LIME MMC, Stockholm, Sweden..
    Banefelt, J.
    Quantify Res, Stockholm, Sweden..
    Toth, E.
    UCB Pharma, Brussels, Belgium..
    Libanati, C.
    UCB Pharma, Brussels, Belgium..
    Charokopou, M.
    UCB Pharma, Brussels, Belgium..
    Risk Of Major Osteoporotic Fracture (Hip, Vertebral, Radius, Humerus [Mof]) After First, Second And Third Fragility Fracture In A Swedish General Population Cohort2017In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, no 9, p. A528-A528Article in journal (Other academic)
  • 25.
    Kalf, R.
    et al.
    Natl Healthcare Inst ZIN, Diemen, Netherlands..
    Makady, A.
    Natl Healthcare Inst ZIN, Diemen, Netherlands..
    Ryll, Bettina
    Uppsala University, Disciplinary Domain of Science and Technology, Biology, Department of Organismal Biology, Evolution and Developmental Biology. Melanoma Patient Network Europe, Uppsala, Sweden..
    Spurrier, G.
    Melanoma Patient Network Europe, Uppsala, Sweden.;Melanome France, Uppsala, Sweden..
    Goettsch, W.
    Natl Hlth Care Inst, Diemen, Netherlands..
    Social Media: A Valuable Tool To Assess Patient Perspectives Regarding Quality Of Life2016In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 19, no 7, p. A749-A749Article in journal (Refereed)
  • 26. Khalid, J. M.
    et al.
    Mushnikov, V
    Vattulainen, P.
    Johansson, Gunnar
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Korhonen, P.
    Hoti, F.
    Patients with COPD who Initiate Roflumilast in Sweden2014In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 17, no 7, p. A590-A590, article id PRS14Article in journal (Other academic)
  • 27.
    Koltowska-Häggström, Maria
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.
    Jonsson, Björn
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health.
    Isacson, Dag
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.
    Bingefors, Kerstin
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.
    Using EQ-5D to derive general population-based utilities for the Quality of Life-Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA)2007In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 10, no 1, p. 73-81Article in journal (Refereed)
    Abstract [en]

    Objective: Disease-oriented quality of life (QoL) measures that are not preference-based lack legitimacy for direct use in cost-utility analyses. This has prompted the search for other methods for deriving utilities. The QoL Assessment of Growth Hormone Deficiency in Adults questionnaire (QoL-AGHDA) is a disease-oriented measure used to assess impairment in QoL in adults with growth hormone deficiency. The present study was designed to generate a model for deriving utilities from the QoL-AGHDA. Methods: The EQ-5D, the QoL-AGHDA, and demographic questions were mailed to a random sample (n = 3005) of the Swedish population (response rate 65%). Multiple regression analysis was used to obtain cross-validated parameters of QoL-AGHDA-based utilities. Two models were developed (simple and full versions). The simple version used the EQ-5Dindex (derived from European values) as the dependent variable, and age, sex, and QoL-AGHDA score as independent variables in a regression analysis. The full model utilized all available demographic information. The QoL-AGHDA scores were thus transformed into a single score (0-1), corresponding to the QoL-AGHDA-based utility. Results: The simple transformation algorithm was U (QoL-AGHDA-based utilities) = 1.05 - 0.0189 x QoL-AGHDA score - 0.00238 x age - 0.0127 x sex (male = 0; female = 1). The mean of the weighted estimate for the population (n =1752) was 0.85 (SD 0.10). The estimate for men (n = 861; mean 0.86; SD 0.10) was higher (P < 0.001) than for women (n = 891; mean 0.84; SD 0.10). Conclusion: For practical reasons, the simple model can be recommended for deriving utilities directly from the QoL-AGHDA for the Swedish population.

  • 28.
    Lenhard, F.
    et al.
    Karolinska Inst, Stockholm, Sweden..
    Ssegonja, Richard
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Social Medicine. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Social medicine/CHAP.
    Andersson, E.
    Karolinska Inst, Stockholm, Sweden..
    Feldman, Inna
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Pediatrics.
    Ruck, C.
    Karolinska Inst, Stockholm, Sweden..
    Mataix-Cols, D.
    Karolinska Inst, Stockholm, Sweden..
    Serlachius, E.
    Karolinska Inst, Stockholm, Sweden..
    Cost-Effectiveness Of Internet-Delivered Cognitive Behavior Therapy For Adolescent Obsessive-Compulsive Disorder2016In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 19, no 7, p. A521-A521Article in journal (Refereed)
  • 29.
    Lesen, E.
    et al.
    Nord Hlth Econ, Gothenburg, Sweden..
    Bjorstad, A.
    Nord Hlth Econ, Gothenburg, Sweden..
    Bjorholt, I
    Nord Hlth Econ, Gothenburg, Sweden..
    Feuilly, M.
    Ipsen Pharma, Boulogne, France..
    Marteau, F.
    Ipsen Pharma, Boulogne, France..
    Gabriel, S.
    Ipsen Pharma, Boulogne, France..
    Elf, A.
    Sahlgrens Univ Hosp, Gothenburg, Sweden..
    Johanson, V
    Sahlgrens Univ Hosp, Gothenburg, Sweden..
    Welin, Staffan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Endocrin Oncology.
    Real-World Resource Use And Costs Of Treating Controlled And Uncontrolled Carcinoid Syndrome: A Retrospective Swedish Study2017In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, no 9, p. A552-A552Article in journal (Other academic)
  • 30. Levin, Lars-Ake
    et al.
    Wallentin, Lars
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, UCR-Uppsala Clinical Research Center.
    Bernfort, Lars
    Andersson, David
    Storey, Robert F.
    Bergstrom, Gina
    Lamm, Carl-Johan
    Janzon, Magnus
    Kaul, Padma
    Health-Related Quality of Life of Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes-Results from the PLATO Trial2013In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 16, no 4, p. 574-580Article in journal (Refereed)
    Abstract [en]

    Objectives: The purpose of this study was to compare the effects of ticagrelor versus clopidogrel on health-related quality of life in the PLATelet inhibition and patient Outcomes (PLATO) trial. Background: The PLATO trial showed that ticagrelor was superior to clopidogrel for the prevention of cardiovascular death, myocardial infarction, or stroke in a broad population of patients with acute coronary syndromes. Methods: HRQOL in the PLATO study was measured at hospital discharge, 6-month visit, and end of treatment (anticipated at 12 months) by using the EuroQol five-dimensional (EQ-5D) questionnaire. All patients who had an EQ-5D questionnaire assessment at discharge from the index hospitalization (n = 15,212) were included in the study. Patients who died prior to the end-of-treatment visit were assigned an EQ-5D questionnaire value of 0. Results: The EQ-5D questionnaire value at discharge among 7631 patients assigned to ticagrelor was 0.847 and among 7581 patients assigned to clopidogrel was 0.846 (P = 0.71). At 12 months, the mean EQ-5D questionnaire value was 0.840 for ticagrelor and 0.832 for clopidogrel (P = 0.046). Excluding patients who died resulted in mean EQ-5D questionnaire values of 0.864 among ticagrelor patients and 0.863 among clopidogrel patients (P = 0.69). Conclusions: In patients hospitalized with acute coronary syndromes with or without ST-segment elevation, treatment with ticagrelor was associated with a lower mortality but otherwise no difference in quality of life relative to treatment with clopidogrel. The improved survival and reduction in cardiovascular events with ticagrelor are therefore obtained with no loss in quality of life.

  • 31. Lundberg, J. G.
    et al.
    Jensen, A. , V
    Bjorkholm, M.
    Höglund, Martin
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Haematology.
    Akerborg, O.
    Cost-Utility Analysis Of Posaconazole Versus Fluconazole For Prevention Of Invasive Fungal Infections In Patients With Graft-Versus- Host Disease In Sweden2013In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 16, no 7, p. A359-A359Article in journal (Other academic)
  • 32.
    Makady, A.
    et al.
    Natl Healthcare Inst ZIN, Diemen, Netherlands..
    Stegenga, H.
    Natl Inst Hlth & Care Excellence, London, England..
    Ciaglia, A.
    Int Alliance Patients Org, London, England..
    Debray, T. P.
    Univ Med Ctr Utrecht, Utrecht, Netherlands..
    Lees, M.
    Bristol Myers Squibb, Rueil Malmaison, France..
    Ryll, B.
    Uppsala University, Disciplinary Domain of Science and Technology, Biology, Department of Cell and Molecular Biology. Melanoma Patient Network Europe, Uppsala, Sweden..
    Abrams, K. R.
    Univ Leicester, Leicester, Leics, England..
    Thwaites, R.
    Takeda, London, England..
    Garner, S.
    NICE, London, England..
    Jonsson, P.
    Natl Inst Hlth & Care Excellence NICE, Manchester, Lancs, England..
    Goettsch, W.
    Univ Utrecht, Utrecht, Netherlands..
    Practicalities Of Using Real-World Evidence (Rwe) In Comparative Effectiveness Research (Cer): Learnings From Imi-Getreal2017In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, no 9, p. A692-A692Article in journal (Other academic)
  • 33. Mascialino, B.
    et al.
    Hermansson, L. L.
    Larsson, Anders
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Anaesthesiology and Intensive Care.
    Cost-effectiveness in diagnostic tests: Comparison of the ibd pre-endoscopic screening f-calprotectin test versus serologic markers in selected european markets2012In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 15, no 7, p. A356-A356Article in journal (Other academic)
  • 34. Mascialino, B.
    et al.
    Hermansson, L. L.
    Larsson, Anders
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Biochemial structure and function.
    Ruling Out IBD In The United Kingdom And Brazil: Is The Usage Of F-Calprotectin In Primary Care Cost-Effective?2013In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 16, no 7, p. A692-A692Article in journal (Other academic)
  • 35. Mascialino, B.
    et al.
    Hermansson, L. L.
    Larsson, Anders
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Biochemial structure and function.
    Ruling Out IBD In The United Kingdom And Spain: Is The Usage Of F-Calprotectin In Primary Care Cost-Effective?2013In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 16, no 7, p. A493-A493Article in journal (Other academic)
  • 36. Mesterton, J.
    et al.
    Hallberg, S.
    Gandra, S. R.
    Banefelt, J.
    Fox, K. M.
    Johansson, Gunnar
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Levin, L. A.
    Sobocki, P.
    LDL-C Goal Attainment in Patients with Hyperlipidemia - Estimates from Population-Based Register Data in Sweden2014In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 17, no 7, p. A497-A497, article id PCV142Article in journal (Other academic)
  • 37. Nordenfelt, P.
    et al.
    Bjorkander, J.
    Mallbris, L.
    Lindfors, A.
    Friberg, S.
    Lofdal, K.
    Nordvall, Lennart
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Pediatrics.
    Werner, S.
    Wahlgren, C. F.
    Quality of life and productivity loss in patients with hereditary angioedema (hae) in sweden; results from a retrospective patient registry survey implemented by sweha-reg (a population based census of hae in sweden)2012In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 15, no 7, p. A557-A557Article in journal (Other academic)
  • 38.
    Nystrand, Camilla
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Social medicine/CHAP.
    Hultkrantz, L.
    Orebro Univ, Orebro, Sweden.
    Vimefall, E.
    Orebro Univ, Orebro, Sweden.
    Sampaio, Filipa
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Social medicine/CHAP.
    Feldman, Inna
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Social medicine/CHAP.
    Indicated Parenting Interventions and Long Term Outcomes: A Health Economic Modeling Study2018In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 21, p. S76-S76Article in journal (Other academic)
  • 39.
    Nystrand, Camilla
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Social Medicine.
    Sampaio, Filipa
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Social Medicine.
    Feldman, Inna
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Social Medicine.
    Cost-Offset Analysis Of Social And Emotional Learning Programs For The Prevention Of Externalizing Behavior Problems: An Economic Modeling Study2017In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, no 5, p. A297-A297Article in journal (Other academic)
    Abstract [en]

    OBJECTIVES: Externalizing behavior problems are common among children,and place a high disease and financial burden on individuals and society. Social and Emotional Learning (SEL) programs are commonly used to prevent such problems, but little is known about their possible longer-term cost-offsets. This study estimates the costs and longer term savings of the two evidence based SEL programs currently available in Sweden, Good Behavior Game and Second Step, for the reduction of externalizing behavior problems in children.

    METHODS: A population-based Markov model was developed to estimate the cost-savings of the two SEL programs compared to a no intervention scenario, achieved by a reduction in clinical cases of attention-deficit/hyperactivity disorder (ADHD), Conduct disorder (CD) and comorbid ADHD/CD. Epidemiological data were collected from the 2015 Global Burden of Disease Study. Intervention effectiveness parameters were estimated from a meta-analysis of relevant studies, where effects assumed to reduce to zero after one year. This study adopted a limited societal perspective including costs accruing to the healthcare and education sectors while intervention costs were based on intervention descriptions. The target population was a cohort of 8-10-year-old healthy children in the 2015 Swedish population followed through to the age of 15 years, assuming 100% intervention coverage. Multivariate probabilistic and univariate sensitivity analyses were conducted to test model assumptions.

    RESULTS: Intervention cost per child amounted to 70 USD and total cost-savings per child over the modeling period were estimated at 330 USD. The cost-offset relationship for prevention was 1.49, implying that for 1 USD invested, 1.49 USD can be gained over the modeling period.

    CONCLUSIONS: Our results suggest that these two evidence based SEL programs are likely to yield cost-savings to society. Further research is needed to investigate cost-savings accruing to other sectors of the society, as well as the cost-effectiveness of such interventions.

  • 40. Patrick, Donald L.
    et al.
    Burke, Laurie B.
    Gwaltney, Chad J.
    Leidy, Nancy Kline
    Martin, Mona L.
    Molsen, Elizabeth
    Ring, Lena
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.
    Content Validity - Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 1 - Eliciting Concepts for a New PRO Instrument2011In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 14, no 8, p. 967-977Article in journal (Refereed)
    Abstract [en]

    The importance of content validity in developing patient reported outcomes (PRO) instruments is stressed by both the US Food and Drug Administration and the European Medicines Agency. Content validity is the extent to which an instrument measures the important aspects of concepts that developers or users purport it to assess. A PRO instrument measures the concepts most significant and relevant to a patient's condition and its treatment. For PRO instruments, items and domains as reflected in the scores of an instrument should be important to the target population and comprehensive with respect to patient concerns. Documentation of target population input in item generation, as well as evaluation of patient understanding through cognitive interviewing, can provide the evidence for content validity. Developing content for, and assessing respondent understanding of, newly developed PRO instruments for medical product evaluation will be discussed in this two-part ISPOR PRO Good Research Practices Task Force Report. Topics include the methods for generating items, documenting item development, coding of qualitative data from item generation, cognitive interviewing, and tracking item development through the various stages of research and preparing this tracking for submission to regulatory agencies. Part 1 covers elicitation of key concepts using qualitative focus groups and/or interviews to inform content and structure of a new PRO instrument. Part 2 covers the instrument development process, the assessment of patient understanding of the draft instrument using cognitive interviews and steps for instrument revision. The two parts are meant to be read together. They are intended to offer suggestions for good practices in planning, executing, and documenting qualitative studies that are used to support the content validity of PRO instruments to be used in medical product evaluation.

  • 41. Patrick, Donald L.
    et al.
    Burke, Laurie B.
    Gwaltney, Chad J.
    Leidy, Nancy Kline
    Martin, Mona L.
    Molsen, Elizabeth
    Ring, Lena
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.
    Content Validity - Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 2 - Assessing Respondent Understanding2011In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 14, no 8, p. 978-988Article in journal (Refereed)
    Abstract [en]

    The importance of content validity in developing patient reported outcomes (PRO) instruments is stressed by both the US Food and Drug Administration and the European Medicines Agency. Content validity is the extent to which an instrument measures the important aspects of concepts developers or users purport it to assess. A PRO instrument measures the concepts most relevant and important to a patient's condition and its treatment. For PRO instruments, items and domains as reflected in the scores of an instrument should be important to the target population and comprehensive with respect to patient concerns. Documentation of target population input in item generation, as well as evaluation of patient understanding through cognitive interviewing, can provide the evidence for content validity. Part 1 of this task force report covers elicitation of key concepts using qualitative focus groups and/or interviews to inform content and structure of a new PRO instrument. Building on qualitative interviews and focus groups used to elicit concepts, cognitive interviews help developers craft items that can be understood by respondents in the target population and can ultimately confirm that the final instrument is appropriate, comprehensive, and understandable in the target population. Part 2 details: 1) the methods for conducting cognitive interviews that address patient understanding of items, instructions, and response options; and 2) the methods for tracking item development through the various stages of research and preparing this tracking for submission to regulatory agencies. The task force report's two parts are meant to be read together. They are intended to offer suggestions for good practice in planning, executing, and documenting qualitative studies that are used to support the content validity of PRO instruments to be used in medical product evaluation.

  • 42. Perrin, A.
    et al.
    Park, J.
    Jacob, J.
    Welin, Staffan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Endocrine Oncology.
    COST-EFFECTIVENESS OF TREATING ADVANCED PROGRESSIVE PANCREATIC NEUROENDOCRINE TUMOR PATIENTS WITH EVEROLIMUS VERSUS SUNITINIB IN SWEDEN2015In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 18, no 3, p. A204-A204Article in journal (Other academic)
  • 43. Pettersson, B
    et al.
    Lindgren, P
    Ringborg, A
    Martinell, Mats
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Stålhammar, Jan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Resource consumption and cost of care the year before and after initiation of insulin theraphy in Swedish patients with type 2 diabetes2010In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 13, no 3, p. A58-A58Article in journal (Other academic)
  • 44. Pettersson, B.
    et al.
    Lindgren, P.
    Ringborg, A.
    Martinell, Mats
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Clinical Epidemiology.
    Stålhammar, Jan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Clinical Epidemiology.
    RESOURCE CONSUMPTION AND COSTS OF CARE THE YEAR BEFORE AND AFTER INITIATION OF INSULIN THERAPY IN SWEDISH PATIENTS WITH TYPE 2 DIABETES2010In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 13, no 3, p. A58-A58Article in journal (Other academic)
  • 45. Pryor, Sydney
    et al.
    Savoye, Mary
    Nowicka, Paulina
    Uppsala University, Disciplinary Domain of Humanities and Social Sciences, Faculty of Social Sciences, Department of Food Studies, Nutrition and Dietetics.
    Price, Gary
    Sharifi, Mona
    Yaesoubi, Reza
    Cost-Effectiveness and Long-Term Savings of the Bright Bodies Intervention for Childhood Obesity2023In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 26, no 8, p. 1183-1191Article in journal (Refereed)
    Abstract [en]

    Objective: To estimate the cost and cost-effectiveness of Bright Bodies, a high-intensity, family-based intervention demonstrated to improve BMI among children with obesity in a randomized controlled trial.

    Methods: We developed a microsimulation model to project 10-year BMI trajectories of 8-16 year-old children with obesity using data from National Longitudinal Surveys and Centers for Disease Control and Prevention growth charts and validated the model using data from the Bright Bodies trial and a follow-up study. We used the trial data to estimate the average reduction in BMI per person-year over 10 years and the incremental costs of Bright Bodies, compared with traditional clinical weight management (control), from a health system perspective in 2020 US dollars. Using results from studies of Medical Expenditure Panel Survey data, we projected long-term obesity-related medical expenditure.

    Results: In the primary analysis, assuming depreciating effects post-intervention, Bright Bodies is expected to achieve an average reduction in BMI of 1.67 kg/m2 (95% Uncertainty Interval: 1.43-1.94) per person-year over 10 years compared with control. The incremental intervention cost of Bright Bodies was $360 ($292-$421) per person compared with the clinical control. However, savings in obesity-related health care expenditure offset these costs and the expected cost-savings of Bright Bodies is $1,126 ($689-$1,693) per person over 10-years. The projected time to achieving cost savings compared with clinical control was 3.58 (2.63-5.17) years.

    Conclusions: While resource-intensive, our findings suggest Bright Bodies is cost-saving compared with clinical control by averting future obesity-related health care costs among children with obesity.

  • 46.
    Russo, Selena
    et al.
    Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology, Milan, Italy; Discipline of Paediatrics, School of Women's and Children's Health, University of New South Wales, Kensington, New South Wales, Australia.
    Jongerius, Chiara
    Department of Medical Psychology—Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
    Faccio, Flavia
    Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology, Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.
    Pizzoli, Silvia F.M.
    Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology, Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.
    Pinto, Cathy Anne
    Department of Pharmacoepidemiology, Merck & Co, Inc, Kenilworth, NJ, USA.
    Veldwijk, Jorien
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Centre for Research Ethics and Bioethics. Erasmus School of Health Policy and Management and Erasmus Choice Modelling Center, Erasmus University, Rotterdam, the Netherlands.
    Janssens, Rosanne
    Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
    Simons, Gwenda
    Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
    Falahee, Marie
    Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
    de Bekker-Grob, Esther
    Erasmus School of Health Policy and Management and Erasmus Choice Modelling Center, Erasmus University, Rotterdam, the Netherlands.
    Huys, Isabelle
    Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
    Postmus, Douwe
    University Medical Center Groningen, Groningen, the Netherlands.
    Kihlbom, Ulrik
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Centre for Research Ethics and Bioethics.
    Pravettoni, Gabriella
    Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology, Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.
    Understanding Patients' Preferences: A Systematic Review of Psychological Instruments Used in Patients' Preference and Decision Studies2019In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 22, no 4, p. 491-501Article, review/survey (Refereed)
    Abstract [en]

    Background

    Research has been mainly focused on how to elicit patient preferences, with less attention on why patients form certain preferences.

    Objectives

    To assess which psychological instruments are currently used and which psychological constructs are known to have an impact on patients' preferences and health-related decisions including the formation of preferences and preference heterogeneity.

    Methods

    A systematic database search was undertaken to identify relevant studies. From the selected studies, the following information was extracted: study objectives, study population, design, psychological dimensions investigated, and instruments used to measure psychological variables.

    Results

    Thirty-three studies were identified that described the association between a psychological construct, measured using a validated instrument, and patients' preferences or health-related decisions. We identified 33 psychological instruments and 18 constructs, and categorized the instruments into 5 groups, namely, motivational factors, cognitive factors, individual differences, emotion and mood, and health beliefs.

    Conclusions

    This review provides an overview of the psychological factors and related instruments in the context of patients' preferences and decisions in healthcaresettings. Our results indicate that measures of health literacy, numeracy, and locus of control have an impact on health-related preferences and decisions. Within the category of constructs that could explain preference and decision heterogeneity, health locus of control is a strong predictor of decisions in several healthcare contexts and is useful to consider when designing a patient preference study. Future research should continue to explore the association of psychological constructs with preference formation and heterogeneity to build on these initial recommendations.

    Download full text (pdf)
    fulltext
  • 47. Sabale, U.
    et al.
    Bodegard, J.
    Sundstrom, J.
    Svennblad, Bodil
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, UCR-Uppsala Clinical Research Center.
    Ostgren, C. J.
    Nilsson, P.
    Johansson, Gunnar
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Henriksson, M.
    Health Care Utilization Following Newly-Diagnosed Type-2 Diabetes In Sweden: A Follow-Up Of 38,956 Patients In A Real Clinical Setting2013In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 16, no 7, p. A451-A451Article in journal (Other academic)
  • 48. Sabale, U.
    et al.
    Bodegard, J.
    Sundström, Johan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, UCR-Uppsala Clinical Research Center.
    Svennblad, Bodil
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, UCR-Uppsala Clinical Research Center. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Orthopaedics.
    Oestgren, C. J.
    Nilsson, P.
    Johansson, Gunnar
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Henriksson, M.
    Association Of Changes In Body Weight With Health Care Costs Among Patients With Newly-Diagnosed Type-2 Diabetes In Sweden2014In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 17, no 7, p. A338-A338Article in journal (Other academic)
  • 49. Sabale, U
    et al.
    Bodegård, J
    Sundström, J
    Svennblad, Bodil
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Orthopaedics.
    Östgren, C J
    Nilsson, P
    Johansson, G
    Henriksson, M
    Association of Changes In Body Weight With Health Care Costs Among Patients With Newly-Diagnosed Type-2 Diabetes In Sweden.2014In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 17, no 7, article id A338Article in journal (Refereed)
  • 50.
    Sampaio, Filipa
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Social medicine/CHAP.
    Bonnert, M.
    Karolinska Inst, Stockholm, Sweden.
    Olen, O.
    Karolinska Inst, Stockholm, Sweden.
    Hedman, E.
    Karolinska Inst, Stockholm, Sweden.
    Lalouni, M.
    Karolinska Inst, Stockholm, Sweden.
    Lenhard, F.
    Karolinska Inst, Stockholm, Sweden.
    Ljotsson, B.
    Karolinska Inst, Stockholm, Sweden.
    Nystrand, Camilla
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Social medicine/CHAP.
    Ssegonja, Richard
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Social medicine/CHAP.
    Serlachius, E.
    Karolinska Inst, Stockholm, Sweden.
    Feldman, Inna
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Social medicine/CHAP.
    Cost-Effectiveness of Internet-Delivered Cognitive Behaviour Therapy for Adolescents with Irritable Bowel Syndrome2018In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 21, p. S42-S42Article in journal (Other academic)
12 1 - 50 of 66
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf